Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) fell 5.7% during trading on Thursday . The company traded as low as $13.65 and last traded at $13.97. 22,031 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 789,017 shares. The stock had previously closed at $14.82.
Analyst Upgrades and Downgrades
A number of brokerages have commented on MESO. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Tuesday, March 4th. Piper Sandler restated an "overweight" rating and issued a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Finally, Jefferies Financial Group downgraded Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Mesoblast has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.
Check Out Our Latest Research Report on MESO
Mesoblast Price Performance
The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average price of $17.77 and a 200-day moving average price of $12.47.
Hedge Funds Weigh In On Mesoblast
Several hedge funds and other institutional investors have recently made changes to their positions in MESO. Creative Planning acquired a new position in shares of Mesoblast during the third quarter worth approximately $147,000. Jane Street Group LLC lifted its position in Mesoblast by 46.4% in the third quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock worth $695,000 after purchasing an additional 26,959 shares during the period. GAMMA Investing LLC lifted its position in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock worth $133,000 after purchasing an additional 1,213 shares during the period. Ballentine Partners LLC acquired a new stake in Mesoblast in the fourth quarter worth approximately $222,000. Finally, R Squared Ltd acquired a new stake in Mesoblast in the fourth quarter worth approximately $30,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
